Results 191 to 200 of about 2,391,041 (267)

International Stakeholder Guidance for Improving Informativeness of Randomized Clinical Trials.

JAMA Netw Open
Prowse SR, Brazzelli M, Green HR, Treweek S.   +3 more
europepmc   +1 more source

CANLead: Canada as a Phase 1 Clinical Trial Leader - Opportunities, Initiatives, and Collaborative Innovation to Elevate National Competitiveness. [PDF]

Oncologist
Adile AA, Sran G, Bedard PL, Carlsson L, Doi J, Drummond-Ivars N, Hakgor S, Henderson A, Hilton JF, Josephy PD, Kremidas J, Limoges J, Renouf DJ, Ross F, Salawu A, Saleh R, Siu LL, Voccia I, Lewis HG, Paquette M, Razak ARA, Spreafico A.   +21 more
europepmc   +1 more source

Design and analysis strategies for robust microbiome ageing research

FEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik, İsmail Güderer, Yi Wang, Tayyaba Alvi, Prasoon Pandey, Handan Melike Dönertaş   +5 more
wiley   +1 more source

A visual framework for classifying adaptive design clinical trials using the GATE frame and PICO terminology. [PDF]

Dialogues Health
Lora D, Lalueza Blanco A, Maestro de la Calle G, García Reyne A, Ruíz-Ruigómez M, Calderón EJ, Menéndez-Orenga M.   +6 more
europepmc   +1 more source

ABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains

FEBS Letters, EarlyView.
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens, Brendan W. Chandler, Anna M. Schmoker, Jaye L. Weinert, Charlotte A. Kearns, Warren T. Yacawych, Amila Šemić, Alicia M. Ebert, Bryan A. Ballif   +8 more
wiley   +1 more source

Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy-Advances through 2026. [PDF]

Regen Ther
Morimoto S, Kato C, Takahashi S, Okano H.   +3 more
europepmc   +1 more source

Reconstructing enzyme evolution by protein engineering

FEBS Letters, EarlyView.
Natural enzyme evolution can be retraced by protein engineering methods such as directed evolution, rational design, and ancestral sequence reconstruction. These approaches reveal how enzymes emerged from ligand‐binding scaffolds, developed varying substrate preferences, formed oligomeric complexes, adapted to environmental changes, and evolved novel ...
Lukas Drexler, Markus R. Busch, Reinhard Sterner   +2 more
wiley   +1 more source

Blockchain Smart Contracts for Automating Clinical Trials: Systematic Review and Proposed System Architecture. [PDF]

JMIR Med Inform
Sheikh Z, Samarth G, Jaffer U.
europepmc   +1 more source

Decoding the dynamic extracellular matrix in cancer—3D models and bioscaffolds rewire the rules of tumor progression

FEBS Letters, EarlyView.
Cancer progression is regulated by the dynamic matrix code of the tumor microenvironment, which influences cellular behavior and disease development. Importantly, matrix remodeling in three‐dimensional cancer models more accurately reflects in vivo conditions compared to conventional two‐dimensional systems.
Sylvia Mangani, Konstantinos Spanopoulos, Zoi Piperigkou, Nikos K. Karamanos   +3 more
wiley   +1 more source